A new study finds that a combination of two monoclonal antibodies can help high-risk COVID-19 patients avoid being hospitalized.
In a study involving nearly 1,400 people with mild to moderate cases of COVID-19, significantly fewer individuals receiving antibody treatment required hospitalization.
Monoclonal antibody treatments for COVID-19 are most effective when people receive the treatment early, according to some experts.
In the study, doctors treated the participants with casirivimab and imdevimab, a combination the FDA has approved for emergency use.
